Literature DB >> 21871297

Activating enhancer-binding protein-2β nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection.

Min P Kim1, Ying Chen, B Nebiyou Bekele, Adriana Lopez, Abha Khanna, Jie Qing Chen, Margaret R Spitz, Carmen Behrens, Luisa Solis, Marnie Wismach, Lin Ji, Ignacio I Wistuba, Jack A Roth, Ruth L Katz.   

Abstract

BACKGROUND: Activating enhancer-binding protein-2β (AP2β) is a transcription factor involved in apoptosis. The purpose of the current study was to assess the cellular location and level of AP2β in non-small cell lung cancer (NSCLC) and normal lung tissue and investigate whether the level and localization of AP2β expression is predictive of overall survival in patients with stage I NSCLC.
METHODS: We performed immunohistochemical analysis of tissue microarrays (TMAs) prepared from stage I NSCLC specimens with adjacent normal lung tissue from two independent sets of patients who underwent lung resection with curative intent at our institution. The AP2β intensity was assessed in TMAs, and AP2β staining patterns were classified as either diffuse or nucleolar in the TMAs. The AP2β intensity and localization were analyzed for correlation with patients' survival.
RESULTS: Immunohistochemical analysis of TMAs showed that the intensity of AP2β immunohistochemical staining did not correlate with overall survival. When location of AP2β was analyzed in TMAs, all of the normal lung tissue had diffuse pattern of AP2β. In the first set of NSCLC, patients with nucleolar pattern had a significantly lower 5-year survival rate than patients with diffuse pattern (67% versus 100%; p=0.004); this finding was confirmed in the second set (64% versus 91%; p=0.02). Multivariate analysis revealed that nucleolar pattern was an independent predictor of poor overall survival in both sets.
CONCLUSIONS: The AP2β, which is located in the nucleoplasm in normal lung tissue, is found in either nucleoplasm or nucleoli in NSCLC. The patients with AP2β in the nucleoli had poor survival compared with patients with AP2β in the cytoplasm.
Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871297      PMCID: PMC3272351          DOI: 10.1016/j.athoracsur.2011.04.029

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  17 in total

Review 1.  Nucleolus and apoptosis.

Authors:  M Horký; V Kotala; M Anton; J Wesierska-Gadek
Journal:  Ann N Y Acad Sci       Date:  2002-11       Impact factor: 5.691

2.  Telomerase reverse transcriptase promoter regulation during myogenic differentiation of human RD rhabdomyosarcoma cells.

Authors:  Hongwen Ma; Virginia Urquidi; Jeremy Wong; Jeanine Kleeman; Steve Goodison
Journal:  Mol Cancer Res       Date:  2003-08       Impact factor: 5.852

3.  Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements.

Authors:  T Williams; A Admon; B Lüscher; R Tjian
Journal:  Genes Dev       Date:  1988-12       Impact factor: 11.361

Review 4.  Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control.

Authors:  K Hilger-Eversheim; M Moser; H Schorle; R Buettner
Journal:  Gene       Date:  2000-12-30       Impact factor: 3.688

5.  The nucleolar localization domain of the catalytic subunit of human telomerase.

Authors:  Katherine T Etheridge; Soma S R Banik; Blaine N Armbruster; Yusheng Zhu; Rebecca M Terns; Michael P Terns; Christopher M Counter
Journal:  J Biol Chem       Date:  2002-04-15       Impact factor: 5.157

6.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

7.  hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.

Authors:  Luo Wang; Jean-Charles Soria; Bonnie L Kemp; Diane D Liu; Li Mao; Fadlo R Khuri
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

Review 8.  Survival in early-stage non-small cell lung cancer.

Authors:  J C Nesbitt; J B Putnam; G L Walsh; J A Roth; C F Mountain
Journal:  Ann Thorac Surg       Date:  1995-08       Impact factor: 4.330

9.  Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells.

Authors:  Masahiko Nishizaki; Ji-Ichiro Sasaki; Bingliang Fang; Edward N Atkinson; John D Minna; Jack A Roth; Lin Ji
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

10.  Immunohistochemical localization of hTERT protein in human tissues.

Authors:  Pu Yan; Jean Benhattar; Walter Seelentag; Jean-Christophe Stehle; Fred T Bosman
Journal:  Histochem Cell Biol       Date:  2004-05-07       Impact factor: 4.304

View more
  3 in total

1.  CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas.

Authors:  Wangbing Chen; Lijun Qin; Shusen Wang; Mei Li; Dingbo Shi; Yun Tian; Jingshu Wang; Lingyi Fu; Zhenglin Li; Wei Guo; Wendan Yu; Yuhui Yuan; Tiebang Kang; Wenlin Huang; Wuguo Deng
Journal:  Mol Oncol       Date:  2014-02-14       Impact factor: 6.603

2.  Transforming growth factor-β1 and α-smooth muscle actin in stromal fibroblasts are associated with a poor prognosis in patients with clinical stage I-IIIA nonsmall cell lung cancer after curative resection.

Authors:  Yongbing Chen; Li Zou; Yongsheng Zhang; Yuanyuan Chen; Pengfei Xing; Wentao Yang; Feng Li; Xiaoqing Ji; Fengjv Liu; Xueguan Lu
Journal:  Tumour Biol       Date:  2014-04-09

3.  Ret finger protein-like 3 promotes tumor cell growth by activating telomerase reverse transcriptase expression in human lung cancer cells.

Authors:  Wangbing Chen; Jianjun Lu; Yu Qin; Jingshu Wang; Yun Tian; Dingbo Shi; Shusen Wang; Yao Xiao; Meng Dai; Lu Liu; Guo Wei; Taihua Wu; Bilian Jin; Xiangsheng Xiao; Tie-Bang Kang; Wenlin Huang; Wuguo Deng
Journal:  Oncotarget       Date:  2014-12-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.